LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 303 participants.
Also called NCT02964247
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 303 participants
- Sponsor
- Registry
-
NCT02964247
-
- Other papers using this trial's data
- Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Brazil, India, Israel, Puerto Rico, Russia, United Arab Emirates
- Registry status
- Completed
Technical summary
Registry record NCT02964247. Randomized; double masking; primary purpose treatment. Start 2017-03-03 (actual); primary completion 2018-05-04 (actual). Results posted on 2019-07-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- liraglutide
- Intervention (Drug)
- placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02964247- Content hash
27a01cf1b636395340edeeed70237abb0937a0eccce515f5cd49dea9b8b23b31